Cathie Wood’s Ark Investment Management sends out an email every night listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have known to cause certain stocks to see a spike in the after-hours session. Here’s a list of 14 stocks that the hedge fund bought and sold on Monday.
Trades For Ark Genomic Revolution ETF ARKG:
Butterfly Network Inc BFLY: Bought 316,100 shares of the medical imaging devices company, representing about 0.0534% of the ETF.
Butterfly shares closed 2.27% higher at $16.64 on Monday and were up 3% in the after-hours. It has a 52-week high of $29.13 and low of $9.34.
908 Devices Inc MASS: Bought 21,256 shares of the purpose-built handheld and devices for chemical and biomolecular analysis maker, representing about 0.011% of the ETF.
908 Devices stock closed 0.73% higher at $52.49 on Monday. It has a 52-week high of $79.60 and low of $38.88.
See Also: Cathie Wood Is Bullish On 908 Devices. An Analyst Makes A Case For The Stock
Repare Therapeutics Inc RPTX: Bought 2,000 shares of the Canadian oncology company, representing about 0.0006% of the ETF.
Repare stock closed 6.01% higher at $31.91 on Monday. It has a 52-week high of $46.44 and low of $21.45.
Signify Health Inc SGFY: Bought 70,299 shares of the healthcare tech company, representing about 0.0204% of the ETF.
Signify stock closed 2.54% lower at $29.12 on Monday. It has a 52-week high of $40.79 and low of $22.13.
Phreesia Inc PHR: Sold 22,100 shares of the healthcare software services company, representing about 0.124% of the ETF.
Phreesia shares closed 0.11% higher at $55.19 on Monday. It has a 52-week high of $81.59 and low of $17.27.
Pluristem Therapeutics Inc PSTI: Sold 23,726 shares of the Israel-based stemcell company, representing about 0.0012% of the ETF.
Pluristem stock closed 2.91% lower at $4.95 on Monday. It has a 52-week high of $13.29 and low of $3.09.
Syros Pharmaceuticals Co SYRS: Sold 68,057 shares of the biopharmaceutical company that focuses on the development of treatments for cancer and monogenic diseases, representing about 0.0052% of the ETF.
Syros stock closed 1.29% higher at $7.48 on Monday. It has a 52-week high of $15.65 and low of $5.14.
Trades For Ark Innovation ETF ARKK:
10X Genomics Inc TXG: Bought 28,606 shares of the gene sequencing biotechnology company, representing about 0.0224% of the ETF.
10X shares closed 2.65% higher at $190.71 on Monday. It has a 52-week high of $201.70 and low of $56.81.
See Also: 10 SPACs Owned By Cathie Wood's Ark Funds
Twitter Inc TWTR: Bought 266,865 shares of the social media app company, representing about 0.695% of the ETF.
Twitter shares closed 0.64% higher at $64.24 on Monday. It has a 52-week high of $80.75 and low of $22.36.
Trimble Inc TRMB Bought 19,346 shares of the California-based hardware, software and services technology company, representing about 0.067% of the ETF.
Trimble shares closed 3.72% higher at $83.74 on Monday. It has a 52-week high of $84.76 and low of $27.79.
Fate Therapeutics FATE: Bought 31,423 shares of the cancer treatment development company, representing about 0.0109% of the ETF.
Fate shares closed 2.14% higher at $83.66 on Monday. It has a 52-week high of $121.16 and low of $19.92.
Beam Therapeutics BEAM: Bought 72,622 shares of the advanced genetic medicines innovator company, representing about 0.0246% of the ETF.
Beam shares closed 1.08% higher at $80.60 on Monday. It has a 52-week high of $126.90 and low of $14.80.
Trades For ARK Next Generation Internet ETF ARKW:
Sea Ltd SE: Bought 75,881 shares of the internet and mobile platform company, representing about 0.2537% of the ETF.
Sea shares closed 0.66% lower at $234.90 on Monday. It has a 52-week high of $285 and low of $40.41.
Tencent Holdings TCEHY: Sold 212,554 shares of the Chinese multinational company, representing about 0.2527% of the ETF.
Tencent stock closed 0.57% lower at $83.36 on Monday. It has a 52-week high of $99.4 and low of $47.55.
Read Next: 5 Stocks Top Analysts Are Bullish On At The Start Of Q2
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
